B.J. Rimel, MD of Cedars Sinai Medical Center discusses the SGO Presidential address and how inspirational it was from SGO 2016.
Author: Editor
B.J. Rimel, MD of Cedars Sinai Medical Center discusses the high number of uterine and BRCA mutations from study focusing on endometrial cancer patients from SGO 2016. Transcription: There is another abstract by doctor ring that looked at and unselected cohort of individual cancer patients that have been panel tested and soon there some pretty remarkable findings from. Paper I specifically that there were urine cancers that had opposed. Surprisingly high number of mutations that were previously unknowns there there are some recommendations in their serious cancers which is really interesting more data will be very valuable and try to…
B.J. Rimel, MD of Cedars Sinai Medical Center discusses the future clinical trials in ovarian cancer from SGO 2016. Transcription: In terms of future clinical trials. There we are selecting more clinical trials based on. Known genetic predispositions be RCA. The potential response to platinum potential response to part now being a sort of thing that we’re looking at. So all of these panel testings are going to lead us down different pathways and so that does make us help a stratified patients for future study for clinical trials. Probably the direction I see that going on right now.
Karen H. Lu, MD of MD Anderson discusses recommendations to physicians whos patients are concerned about their risk of ovarian cancer from SGO 2016.
Karen H. Lu, MD of MD Anderson discusses how genetic testing improves early detection of BRCA in at risk women for ovarian cancer from SGO 2016.
Karen H. Lu, MD of MD Anderson discusses genomic analysis and prophylactic surgical management for women with inherited genetic abnormalities from SGO 2016.
Karen H. Lu, MD of MD Anderson discusses genetic counseling and prophylactic measures for women at high risk for ovarian cancer from SGO 2016.
Karen H. Lu, MD of MD Anderson says that all women with ovarian cancer should undergo genomic testing for BRCA mutation from SGO 2016.
Thomas Herzog, MD of UC Health discusses preoperative staging and likelihood of R0 resection in gynecologic cancer at SGO 2016.
Thomas Herzog, MD of UC Health discusses neoadjuvant regimen for patients with ovarian cancer at SGO 2016.
Thomas Herzog, MD of UC Health discusses GOG-172 and the ability to modify the Armstrong regimen for greater tolerability at SGO 2016.
Thomas Herzog, MD of UC Health discusses neoadjuvant chemotherapy compromise postoperative recovery at SGO 2016.
Thomas Herzog, MD of UC Health discusses age and the decision to use intraperitoneal chemotherapy in ovarian cancer at SGO 2016.
Martee L. Hensley, MD of Memorial Sloan Kettering discusses how trabectedin improves PFS over Dacarbazine in uterine leiomyosarcoma at SGO 2016.
Martee L. Hensley, MD of Memorial Sloan Kettering discusses trabectedin improves patients with drug resistant metastatic leiomyosarcoma at SGO 2016.
Martee L. Hensley, MD of Memorial Sloan Kettering discusses gynecologic cancer treatment trends at SGO 2016.
Martee L. Hensley, MD of Memorial Sloan Kettering discusses GOG-86P results and genetic testing among most notable data released at SGO 2016.
Martee L. Hensley, MD of Memorial Sloan Kettering discusses genomic analysis and immunotherapy are treatments to watch in gynecologic malignancies at SGO 2016.
Michael J. Birrer, MD of Massachusetts General Hospital discusses toxicities of anti-PD-1 and anti-PD-L1 in gynecologic cancers at SGO 2016. Transcription: Database here is very limited said there’s been one study of about twenty patients an ovary. There’s been an adorable studies in cervix and endometrial cancer so we don’t have a big and. To look at toxicities it’s probably better to extrapolate. From the larger studies in lung cancer and melanoma and real cell in the bottom line is that he’s ageism extremely well tolerated. Yes skin rash is good za and some fifty. The biggest concern is auto…
Michael J. Birrer, MD of Massachusetts General Hospital discusses the unique side effects of trabectedin at SGO 2016. Transcription: The main talks isn’t your back is seen in the ovarian cancer trial was essentially miles suppression. It affects the bone marrow presumably through targeting the minor groove of DNA. Wheat you do see elevated liver function tests. And that is of some concern. And so patients who have elevated liver function tests prior to initiation drug may not be candidates to be treated with this. Rather mile isis I’ve actually not seen a case I would if I did manage…
Michael J. Birrer, MD of Massachusetts General Hospital discusses promising immunotherapy currently under evaluation for advance gynecologic cancers at SGO 2016. Transcription: Well I think the checkpoint hitters are the hot ones partly because they they’ve got eggs terrific track record and other tumors into easy to give their antibodies but it’s been a long track record of immunotherapy. In gynecologic cancers the the. Pennsylvania group where George Lucas was now Georges and in Switzerland was doing adopted TCL approaches and there were some promising results with that the problem is it’s it’s. Resource intensive credibly expensive and toxic. But…
Is there a reliable test to determine whether a patient has a tendency to develop blood clots? Andrew Schorr asks MPN expert Dr. Naval Daver of MD Anderson Cancer Center to answer this and related questions. Dr. Daver explores the reasoning and methodology behind thrombotic screening. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Michael J. Birrer, MD of Massachusetts General Hospital discusses PDL-1 and immune checkpoint inhibitors in endometrial cancer at SGO 2016. Transcription: And the short answer is not a lot and meet your cancer. Has not been one of the first tumors explored for immunotherapy a really was melanoma and real sal. The second wave is involving ovary and. Other tumors in endometrial is probably closer to the third wave. Suffice it to say PT one is expressed. Our and it’s likely that PPL one will also be expressed. We have no clue whether that’s predictive. For. Response.
The international Consensus Conference for Advanced Breast Cancer (ABC) has established itself as a major international breast cancer conference. Its primary aim is the development of international consensus guidelines for the management of ABC patients. These guidelines are based on the most up-to-date evidence and can be used to guide treatment decision making in many different health care settings globally, with the necessary adaptations due to different access to care.
Michael J. Birrer, MD of Massachusetts General Hospital discusses ovarian cancer is targetable with PARP inhibitors at SGO 2016. Transcription: Because because ovarian cancer has this defect in DNA repair. And you see this sort of gross shifting of DNA. How chromosomal abnormalities it has been argued that this tumors not target herbal. And the truth is that it is. You can target the DNA repair process very effectively I think with part innovators and maybe apartment either combinations. And then to the low frequency mutations which do exist but the low frequency once we understand the biology better. It’s…
Michael J. Birrer, MD of Massachusetts General Hospital discusses multiplex testing and next generation sequencing in metastatic ovarian cancer at SGO 2016. Transcription: So this is a really high question. Because there are many many commercially available platforms which provide a lot of genomic data both for the physician and the patient. I and I think frankly is more often than not confusing. For both individuals. What I recommend because. Ovarian cancer is a disease of genomics chaos. There’s a very low frequency of actionable mutations and even when you see a mutation in a gene that you think is…
Michael J. Birrer, MD of Massachusetts General Hospital discusses mirvetuximab soravtansin side effects compared to other systemic treatments in heavily pretreated OC at SGO 2016. Transcription: Ameritech some have survey and seeing is a antibody drug kanji and by definition these are drugs he’s our agency does specifically to the tumor. The distribution of fully receptor alpha in ovarian cancer patients is as almost solely locator on the. I cancer cells there’s a low level expression in the kidney tubules and some expression on type two alveolar cells begin see right there is extremely selective. So the side effects are…
Michael J. Birrer, MD of Massachusetts General Hospital discusses HPV-related cervical cancer with anti-PD-1 and anti-PDL-1 antibodies at SGO 2016. Transcription: So I think from a theoretical standpoint. Cervical cancer should be the poster child for immunotherapy. I sencha understand these tumors. Result in infection from HP vis vis vis vis genome is there E. seven any six are usually expressed these are foreign and agents these are viral infections. So if the immune system is. Op inactivated. Ended tumors producing some of these in him dory prophecies if you use an anti PDL-1 one or anti PD-1 you should.…
Michael J. Birrer, MD of Massachusetts General Hospital discusses guidelines for micro satellite instability or MSI testing for endometrial patients at SGO 2016. Transcription: So we established a. Policy and mass general to stain for MSH six. And other mismatch repair proteins. In. Patients who have an image of cancer under the age of fifty. That is consistent with the NCC and guidelines. Yes Yohe guidelines actually puts the age limit at six. And my guess is with time we will be doing on on everybody. A because it has a bit of a fairly large impact. In that Frizzle…
Michael J. Birrer, MD of Massachusetts General Hospital discusses current actionable mutations in advanced ovarian cancer at SGO 2016. Transcription: I think all of the genes and there’s probably between twenty and thirty of them are that are looking to Fanconi DNA repair pathway I would be important to look at they may ascribe homologous recombination deficiency to the tumor in which case those patients would benefit from apartment a better doesn’t have to be at the time of initial diagnosis. But knowing it would be important in the recurrent setting that the patient that would be a candidate for…
Elizabeth Swisher MD of the University Of Washington discusses Vice President Bidens initiative to increase clinical trials for women with ovarian cancer at SGO 2016.
Elizabeth Swisher MD of the University Of Washington discusses using Next Generation Genetic Sequencing to determine what fraction of ovarian cancer are caused by heredity at SGO 2016.
Elizabeth Swisher MD of the University Of Washington discusses ovarian cancer focus for 2016 to include genetic analysis and target therapies at SGO 2016.
Elizabeth Swisher MD of the University Of Washington discusses how genomic analysis will strengthen prophylactic surgical management in inherited genetic abnormalities at SGO 2016.
Elizabeth Swisher MD of the University Of Washington discusses how genomic analysis may improve prevention, screening and management of inherited ovarian cancer at SGO 2016.
Elizabeth Swisher MD of the University Of Washington discusses the clinical factors for requesting a genomic analysis for at risk patients at SGO 2016
At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Giuseppe Curigliano, MD, PhD, from Istituto Europeo di Oncologia, Milan, Italy, discusses treatment-induced amenorrhoea and overall survival in pre-menopausal breast cancer patients; nipple-sparing mastectomy and outcomes from a national multicentre registry; and pathologic prognostic factors of male breast cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Triple-negative breast cancer (TNBC) represents a biologically and clinically heterogeneous disease. At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Martine Piccart-Gebhart, MD, PhD, from Jules Bordet Institute, Brussels, Belgium, discusses the role of chemotherapy; targeted therapies, including anti-VEGF monoclonal antibody bevacizumab and poly (ADP-ribose) polymerase (PARP) inhibitors; and immunotherapy for the treatment of patients with TNBC. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Fatima Cardoso, MD, from the Champalimaud Clinical Center, Lisbon, Portugal, discusses the themes of the conference, including the manifesto calling for European patients with breast cancer to be cared for in specialist breast units and the emphasis on the clinical application of new research. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the German Cancer Congress 2016, held in Berlin, Germany from 24 to 27 February 2016, Viktor Grünwald, MD, PhD, from Hannover Medical School, Hannover, Germany, highlights recent advances in the treatment of patients with head and neck cancer, including the increasing interest in immunotherapy with the programmed death (PD-1) inhibitors, pembrolizumab and nivolumab. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Martin Reck, MD, PhD, from the LungenClinic Grosshansdorf, Grosshansdorf, Germany, discusses the efficacy and safety of immunotherapy for patients with non-small cell lung cancer. Promising agents include the anti-PD1 antibodies, nivolumab and pembrolizumab; the anti-PD-L1 antibodies, atezolizumab, durvalumab and avelumab; and anti-CTLA-4 antibodies, ipilimumab and tremelimumab. Challenges exist with determining how these immunotherapy approaches can be integrated in clinical practice, in order to, for example, exploit their favourable toxicity profile while avoiding immune-related adverse events. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Matthias Löhr, MD, PhD, from Karolinska Institutet, Stockholm, Sweden, discusses the application of next-generation sequencing for guiding cancer treatment decision-making. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the German Cancer Congress 2016, held in Berlin, Germany from 24 to 27 February 2016, Viktor Grünwald, MD, PhD, from Hannover Medical School, Hannover, Germany, reviews ongoing clinical trials for the treatment of patients with metastatic renal cell carcinoma, including investigations of nivolumab versus everolimus; cabozantinib versus everolimus; and lenvatinib combined with everolimus. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Martin Reck, MD, PhD, from the LungenClinic Grosshansdorf, Grosshansdorf, Germany, discusses immunotherapy as an option for patients with non-small cell lung cancer (NSCLC) who progress after initial treatment, as well as programmed death-ligand 1 (PD-L1) expression as a predictive biomarker for the development of immunotherapy. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Matthias Löhr, MD, PhD, from Karolinska Institutet, Stockholm, Sweden, discusses the clinical value of next-generation sequencing for cancer management, including the accelerating trend towards evidence-based, multigene-driven personalised cancer therapeutics. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Why are researchers and physicians so excited about combination CLL therapy? Patient Power Founder Andrew Schorr sits down with CLL experts Dr. John Gribben, Dr. Constantine Tam and Dr. William Wierda for a CLL roundtable to discuss the rationale behind treatment combinations. Note as they mention key factors such as toxicity overlap and statistical resistance. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
In this Ask the Expert segment, MPN expert Dr. Naval Daver of MD Anderson Cancer Center explains why the current pacritinib trial is on hold and shares the positive and negative learnings thus far. Dr. Daver applauds the FDA for the hold but still views pacritinib as a valuable addition to the MPN (myeloproliferative neoplasm) armamentarium. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Why are researchers and physicians so excited about combination CLL therapy? Patient Power Founder Andrew Schorr sits down with CLL experts Dr. John Gribben, Dr. Constantine Tam and Dr. William Wierda for a CLL roundtable to discuss the rationale behind treatment combinations. Note as they mention key factors such as toxicity overlap and statistical resistance. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Christoph Röllig, MD, from the University Hospital Carl Gustav Carus, Dresden, Germany, reviews the clinical development of new treatment options for patients with acute myeloid leukemia, including tyrosine kinase inhibitors, monoclonal antibodies and chimeric antigen receptor (CAR) T-cell therapy.
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Wolfgang Hiddemann, MD, PhD, from the University of Munich, Munich, Germany, provides an overview of chemotherapy-free approaches in clinical development for the treatment of patients with indolent lymphoma. Promising approaches include the Bruton tyrosine kinase inhibitor, ibrutinib, and PI3K-delta inhibitor, idelalisib, in combinations with anti-CD20 monoclonal antibodies; Bcl-2 inhibitors; and PD-1 immune checkpoint inhibitors.